Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial.
Sosa S, Bringas G, Urrutia N, Peñalver AI, López D, González E, Fernández A, Hernández ZM, Viña A, Peña Y, Batista JF, Valenzuela C, León K, Crombet T, Rodríguez T, Pérez L; ATHENEA Investigators. Sosa S, et al. Among authors: crombet t. Alzheimers Res Ther. 2023 Dec 13;15(1):215. doi: 10.1186/s13195-023-01356-w. Alzheimers Res Ther. 2023. PMID: 38093366 Free PMC article. Clinical Trial.
Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, Neninger E, Pérez M, Sánchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N. Torres LA, et al. Among authors: crombet t. Nucl Med Commun. 2005 Dec;26(12):1049-57. doi: 10.1097/00006231-200512000-00002. Nucl Med Commun. 2005. PMID: 16264350 Clinical Trial.
Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
Díaz Y, Ramos-Suzarte M, Martín Y, Calderón NA, Santiago W, Viñet O, La O Y, Oyarzábal JPA, Pérez Y, Lorenzo G, Cepeda M, Saavedra D, Mazorra Z, Estevez D, Lorenzo-Luaces P, Valenzuela C, Caballero A, Leon K, Crombet T, Hidalgo CJ. Díaz Y, et al. Among authors: crombet t. Gerontology. 2020;66(6):553-561. doi: 10.1159/000512210. Epub 2020 Oct 26. Gerontology. 2020. PMID: 33105142 Free PMC article. Clinical Trial.
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.
Saavedra D, Añé-Kourí AL, Sánchez N, Filgueira LM, Betancourt J, Herrera C, Manso L, Chávez E, Caballero A, Hidalgo C, Lorenzo G, Cepeda M, Valenzuela C, Ramos M, León K, Mazorra Z, Crombet T. Saavedra D, et al. Among authors: crombet t. Immun Ageing. 2020 Nov 14;17(1):34. doi: 10.1186/s12979-020-00207-8. Immun Ageing. 2020. PMID: 33292350 Free PMC article.
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.
Caballero A, Filgueira LM, Betancourt J, Sánchez N, Hidalgo C, Ramírez A, Martinez A, Despaigne RE, Escalona A, Diaz H, Meriño E, Ortega LM, Castillo U, Ramos M, Saavedra D, García Y, Lorenzo G, Cepeda M, Arencibia M, Cabrera L, Domecq M, Estévez D, Valenzuela C, Lorenzo P, Sánchez L, Mazorra Z, León K, Crombet T. Caballero A, et al. Among authors: crombet t. Clin Transl Immunology. 2020 Nov 25;9(11):e1218. doi: 10.1002/cti2.1218. eCollection 2020. Clin Transl Immunology. 2020. PMID: 33304584 Free PMC article.
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.
Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T. Rodríguez MO, et al. Among authors: crombet t. Cancer Biol Ther. 2010 Mar 1;9(5):343-9. doi: 10.4161/cbt.9.5.10981. Epub 2010 Mar 20. Cancer Biol Ther. 2010. PMID: 20448462 Clinical Trial.
58 results